Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gaia Mancuso

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
BMJ (Clinical Research Ed.)|June 18, 2020
Advances in the diagnosis and management of IgG4 related diseaseMarco Lanzillotta, Gaia Mancuso, Emanuel Della-Torre
Rheumatology (Oxford, England)|November 8, 2019
Colchicine as a new therapeutic option for antithyroid arthritis syndromeGaia Mancuso, Nicola Boffini, Lorenzo Dagna, et al.
The Journal of Allergy and Clinical Immunology|April 25, 2023
Type 1 diabetes and inborn errors of immunity: Complete strangers or 2 sides of the same coin?Gaia Mancuso, Camillo Bechi Genzano, Alessandra Fierabracci, et al.
International Journal of Environmental Research and Public Health|November 10, 2020
IgG4-Related Disease of the Oral Cavity. Case Series from a Large Single-Center Cohort of Italian PatientsAndrea Rampi, Marco Lanzillotta, Gaia Mancuso, et al.
Dermatopathology (Basel, Switzerland)|January 21, 2026
Behçet-like Syndromes: A Comprehensive ReviewGaia Mancuso, Igor Salvadè, Adam Ogna, et al.
Seminars in Arthritis and Rheumatism|June 18, 2021
Utility of the "2019 ACR/EULAR classification criteria" for the management of patients with IgG4-related diseaseEmanuel Della-Torre, Marco Lanzillotta, Tommaso Germanò, et al.
Rheumatology (Oxford, England)|June 28, 2020
Clinical phenotypes of IgG4-related disease reflect different prognostic outcomesMarco Lanzillotta, Corrado Campochiaro, Gaia Mancuso, et al.
European Journal of Internal Medicine|January 2, 2021
Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort studyEmanuel Della-Torre, Marco Lanzillotta, Corrado Campochiaro, et al.
ERJ Open Research|October 21, 2022
Corticosteroid-induced remission and mycophenolate maintenance therapy in granulomatous lymphocytic interstitial lung disease: long-term, longitudinal change in lung function in a single-centre cohortHeba M Bintalib, David M Lowe, Gaia Mancuso, et al.
Rheumatology (Oxford, England)|April 15, 2021
Persistence of circulating T-follicular helper cells after rituximab is associated with relapse of IgG4-related diseaseGaia Mancuso, Tatiana Jofra, Marco Lanzillotta, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
BMJ (Clinical Research Ed.)|June 18, 2020
Advances in the diagnosis and management of IgG4 related diseaseMarco Lanzillotta, Gaia Mancuso, Emanuel Della-Torre
Rheumatology (Oxford, England)|November 8, 2019
Colchicine as a new therapeutic option for antithyroid arthritis syndromeGaia Mancuso, Nicola Boffini, Lorenzo Dagna, et al.
The Journal of Allergy and Clinical Immunology|April 25, 2023
Type 1 diabetes and inborn errors of immunity: Complete strangers or 2 sides of the same coin?Gaia Mancuso, Camillo Bechi Genzano, Alessandra Fierabracci, et al.
International Journal of Environmental Research and Public Health|November 10, 2020
IgG4-Related Disease of the Oral Cavity. Case Series from a Large Single-Center Cohort of Italian PatientsAndrea Rampi, Marco Lanzillotta, Gaia Mancuso, et al.
Dermatopathology (Basel, Switzerland)|January 21, 2026
Behçet-like Syndromes: A Comprehensive ReviewGaia Mancuso, Igor Salvadè, Adam Ogna, et al.
Seminars in Arthritis and Rheumatism|June 18, 2021
Utility of the "2019 ACR/EULAR classification criteria" for the management of patients with IgG4-related diseaseEmanuel Della-Torre, Marco Lanzillotta, Tommaso Germanò, et al.
Rheumatology (Oxford, England)|June 28, 2020
Clinical phenotypes of IgG4-related disease reflect different prognostic outcomesMarco Lanzillotta, Corrado Campochiaro, Gaia Mancuso, et al.
European Journal of Internal Medicine|January 2, 2021
Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort studyEmanuel Della-Torre, Marco Lanzillotta, Corrado Campochiaro, et al.
ERJ Open Research|October 21, 2022
Corticosteroid-induced remission and mycophenolate maintenance therapy in granulomatous lymphocytic interstitial lung disease: long-term, longitudinal change in lung function in a single-centre cohortHeba M Bintalib, David M Lowe, Gaia Mancuso, et al.
Rheumatology (Oxford, England)|April 15, 2021
Persistence of circulating T-follicular helper cells after rituximab is associated with relapse of IgG4-related diseaseGaia Mancuso, Tatiana Jofra, Marco Lanzillotta, et al.
Pageof 2